Erythromycin (cas 114-07-8) acts through the ghrelin receptor to attenuate inflammatory responses in chondrocytes and maintain joint integrity
-
Add time:08/23/2019 Source:sciencedirect.com
Osteoarthritis (OA) is a prevalent disease characterized by chronic joint degeneration and low-grade localized inflammation. There is no available treatment to delay OA progression. We report that in human primary articular chondrocytes, Erythromycin (cas 114-07-8), a well-known macrolide antibiotic, had the ability to inhibit pro-inflammatory cytokine Interleukin 1β (IL-1β)-induced catabolic gene expression and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation. Furthermore, erythromycin inhibited monosodium iodoacetate (MIA)-induced joint inflammation and cartilage matrix destruction in mice, an arthritis model that reflects the inflammatory and cartilage matrix loss aspects of OA. EM900, an erythromycin-derivative lacking antibiotic function, had the same activity as erythromycin in vitro and in vivo, indicating distinct anti-inflammatory and antibiotic properties. Using an antibody against erythromycin, we found erythromycin was present on chondrocytes in a dose-dependent manner. The association of erythromycin with chondrocytes was diminished in ghrelin receptor null chondrocytes, and administration of the ghrelin ligand prevented the association of erythromycin with chondrocytes. Importantly, the anti-inflammatory activity of erythromycin was diminished in ghrelin receptor null chondrocytes. Moreover, erythromycin could not exert its chondroprotective effect in ghrelin receptor null mice, and the loss of ghrelin receptor further augmented joint damage upon MIA-injection. Therefore, our study identified a novel pharmacological mechanism for how erythromycin exerts its chondroprotective effect. This mechanism entails ghrelin receptor signaling, which is necessary for alleviating inflammation and joint destruction.
We also recommend Trading Suppliers and Manufacturers of Erythromycin (cas 114-07-8). Pls Click Website Link as below: cas 114-07-8 suppliers
Prev:Partitioning isotherm and kinetic of Erythromycin (cas 114-07-8) into mixed reverse micelle during forward transfer
Next:Erythromycin (cas 114-07-8) degradation and ERY-resistant gene inactivation in Erythromycin (cas 114-07-8) mycelial dreg by heat-activated persulfate oxidation) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Isooctane-based anionic and zwitterionic surfactant: Synergistic interaction of mixed reverse micelle and solubilisation of Erythromycin (cas 114-07-8)08/30/2019
- A new lipid-based oral delivery system of Erythromycin (cas 114-07-8) for prolong sustain release activity08/29/2019
- Erythromycin (cas 114-07-8) relaxes BALB/c mouse airway smooth muscle08/28/2019
- Bioinspired Pt-free molecularly imprinted hydrogel-based magnetic Janus micromotors for temperature-responsive recognition and adsorption of Erythromycin (cas 114-07-8) in water08/27/2019
- Inhibitory effects of dissolved organic matter on Erythromycin (cas 114-07-8) bioavailability and possible mechanisms08/26/2019
- Original ResearchObstetricsAzithromycin vs Erythromycin (cas 114-07-8) for the management of preterm premature rupture of membranes08/25/2019
- Erythromycin (cas 114-07-8) degradation and ERY-resistant gene inactivation in Erythromycin (cas 114-07-8) mycelial dreg by heat-activated persulfate oxidation08/24/2019
- Partitioning isotherm and kinetic of Erythromycin (cas 114-07-8) into mixed reverse micelle during forward transfer08/22/2019
- Synthesis of the Erythromycin (cas 114-07-8)-conjugated nanodendrimer and its antibacterial activity08/21/2019
-
Health and Chemical more >